Research Analysts’ Weekly Ratings Changes for Beta Bionics (BBNX)

Several brokerages have updated their recommendations and price targets on shares of Beta Bionics (NASDAQ: BBNX) in the last few weeks:

• 11/13/2025 – Beta Bionics had its “sell (d-)” rating reaffirmed by analysts at Weiss Ratings.
• 11/1/2025 – Beta Bionics was upgraded by analysts at Wall Street Zen from a “strong sell” rating to a “hold” rating.
• 10/29/2025 – Beta Bionics had its “buy” rating reaffirmed by analysts at Lake Street Capital. They now have a $35.00 price target on the stock.
• 10/29/2025 – Beta Bionics had its “buy” rating reaffirmed by analysts at Stifel Nicolaus. They now have a $31.00 price target on the stock, up previously from $26.00.
• 10/29/2025 – Beta Bionics had its price target raised by analysts at The Goldman Sachs Group, Inc. from $26.00 to $33.00. They now have a “buy” rating on the stock.
• 10/29/2025 – Beta Bionics was given a new $23.00 price target on by analysts at Robert W. Baird.
• 10/29/2025 – Beta Bionics had its “buy” rating reaffirmed by analysts at Truist Financial Corporation. They now have a $32.00 price target on the stock, up previously from $28.00.
• 10/29/2025 – Beta Bionics had its “overweight” rating reaffirmed by analysts at Piper Sandler. They now have a $32.00 price target on the stock, up previously from $26.00.
• 10/21/2025 – Beta Bionics is now covered by analysts at Stifel Nicolaus. They set a “buy” rating and a $26.00 price target on the stock.
• 10/8/2025 – Beta Bionics had its “sell (d)” rating reaffirmed by analysts at Weiss Ratings.
• 10/1/2025 – Beta Bionics was given a new $26.00 price target on by analysts at The Goldman Sachs Group, Inc.. They now have a “buy” rating on the stock.
• 10/1/2025 – Beta Bionics was upgraded by analysts at The Goldman Sachs Group, Inc. from a “hold” rating to a “buy” rating. They now have a $26.00 price target on the stock, up previously from $18.00.
• 9/27/2025 – Beta Bionics had its “sell (d)” rating reaffirmed by analysts at Weiss Ratings.
• 9/22/2025 – Beta Bionics had its price target raised by analysts at Truist Financial Corporation from $21.00 to $28.00. They now have a “buy” rating on the stock.

Insider Activity

In other news, insider Mark Hopman sold 16,158 shares of the stock in a transaction dated Tuesday, August 19th. The stock was sold at an average price of $16.61, for a total value of $268,384.38. Following the completion of the sale, the insider owned 34,132 shares in the company, valued at approximately $566,932.52. This trade represents a 32.13% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Maria Palasis sold 1,406 shares of the firm’s stock in a transaction on Friday, October 31st. The shares were sold at an average price of $26.91, for a total value of $37,835.46. Following the completion of the sale, the director owned 9,841 shares in the company, valued at $264,821.31. The trade was a 12.50% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last quarter, insiders sold 71,713 shares of company stock worth $1,390,158.

Beta Bionics, Inc is a commercial-stage medical device company. It engages in the design, development, and commercialization of solutions for insulin-requiring people with diabetes. The company was founded by Edward R. Damiano on October 21, 2015 and is headquartered in Irvine, CA.